World Journal of Advanced Research and Reviews
eISSN: 2581-9615 CODEN (USA): WJARAI
Cross Ref DOI: 10.30574/wjarr
Journal homepage: https://wjarr.com/

(REVIEW ARTICLE)

Research Trends on the Efficacy of Antidepressant Medications in Adults with Major Depressive Disorder

Mutaz Maawia Osman *

Taaf Organization for Psychiatry & Addiction Awareness, Department of Research, Sudan.

World Journal of Advanced Research and Reviews, 2025, 26(02), 3858–3866

Article DOI: https://doi.org/10.30574/wjarr.2025.26.2.2080

Abstract

Major Depressive Disorder (MDD) is a prevalent psychiatric condition characterized by significant emotional and functional impairments. This review aims to examine recent research on the efficacy of antidepressant medications in adults, focusing on drug classes such as SSRIs, SNRIs, TCAs, MAOIs, and novel agents like ketamine. It synthesizes findings from meta-analyses, pharmacogenetic studies, and advancements in neuroimaging, highlighting a shift toward personalized psychiatry. An evidence-based intervention protocol is proposed, integrating pharmacotherapy with psychotherapeutic approaches, including CBT, ACT, and IPT. Despite advancements, challenges persist in treatment accessibility, resistance, and long-term efficacy. The review advocates for integrated, patient-centered models addressing both biological mechanisms and systemic barriers to optimize MDD management.

Keywords: Major Depressive Disorder; Antidepressants; Pharmacotherapy; Personalized Psychiatry

1. Introduction

Major Depressive Disorder (MDD), often referred to as clinical depression, is a severe psychiatric condition that impairs emotional regulation, cognitive processing, and behavioral functioning. According to the American Psychiatric Association (APA), it manifests not only as persistent low mood or loss of interest but also through symptoms such as impaired concentration, fatigue, appetite disturbance, agitation, and suicidality (Millard, 2022). Unlike transient emotional responses to life events, MDD presents as a prolonged and disabling condition that significantly disrupts occupational, social, and personal domains.

Globally, MDD affects over 300 million people, making it one of the leading causes of disability. The World Health Organization (WHO) reported it as the third-largest contributor to the global burden of disease in 2018, with projections indicating it may become the leading cause by 2030 (Malhi & Mann, 2018). Diagnostic criteria, as outlined in the DSM-5, require five or more symptoms—one of which must be either depressed mood or anhedonia—persisting for at least two weeks and resulting in functional impairment (Bains & Abdijadid, 2023). While its onset often occurs in adulthood, vulnerable populations such as adolescents, the elderly, and pregnant women show heightened prevalence due to genetic, hormonal, and psychosocial factors (Cui et al., 2024).

Pharmacological treatment—particularly antidepressant medication—remains a cornerstone of clinical management. Yet, despite advances in neuropharmacology, questions remain regarding the relative efficacy, tolerability, and personalization of antidepressants across diverse adult populations (Möller, 2008; Richelson, 2001). Emerging research now emphasizes the need to align treatment strategies with individual biological profiles, treatment histories, and psychosocial contexts (Elias et al., 2022).

This paper offers a critical review of current research concerning the efficacy of antidepressant medications in adults with Major Depressive Disorder (MDD). It explores recent developments in pharmacological treatment, examines

* Corresponding author: Mutaz Maawia Osman

comparative outcomes across drug classes, and considers the growing emphasis on integrating medication with individualized treatment planning. Particular attention is given to research trends that inform clinical decision-making, including findings from large-scale meta-analyses, advances in pharmacogenetics, and the incorporation of combined therapeutic approaches. The aim is to present clinically meaningful insights that support more tailored, evidence-informed strategies for managing depression in adult populations.

2. Understanding Major Depressive Disorder

2.1. Prevalence and Diagnostic Criteria

Major Depressive Disorder (MDD) is clinically characterized by a persistent depressed mood or marked loss of interest or pleasure, accompanied by a constellation of cognitive, emotional, and somatic symptoms. According to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), a diagnosis requires the presence of at least five symptoms—such as appetite or weight changes, insomnia or hypersomnia, fatigue, feelings of worthlessness, diminished concentration, or recurrent thoughts of death—lasting for a minimum of two weeks, with at least one being either a depressed mood or anhedonia (APA, 2013; Tolentino & Schmidt, 2018).

The global prevalence of MDD is estimated to range between 5% and 17%, with a lifetime mean of around 12% (Pan et al., 2019). Diagnostic thresholds, cultural context, and the accessibility of mental health services influence this variability. Notably, the disorder disproportionately affects women, who are nearly twice as likely as men to be diagnosed with MDD (Navneet Bains & Abdijadid, 2023). Several factors contribute to this disparity, including hormonal fluctuations related to reproductive cycles, the psychosocial burden of caregiving roles, and differential exposure to interpersonal trauma. For instance, variations in estrogen and progesterone have been shown to influence serotonin regulation, thereby impacting mood stability. Moreover, gendered societal norms can reinforce learned helplessness and discourage help-seeking among women, compounding the risk of chronic stress and depressive episodes.

While epidemiological data consistently indicate that women have higher rates of Major Depressive Disorder (MDD), men are disproportionately represented in suicide mortality statistics. This widely recognized "gender paradox in suicide" reflects fundamental differences in emotional regulation, coping mechanisms, and help-seeking behavior. Men are less likely to disclose psychological distress or seek mental health services, largely due to cultural expectations surrounding masculinity and emotional detachment. As a result, depressive symptoms often remain unrecognized and untreated, escalating the risk of suicide. Moreover, men tend to employ more lethal means—such as firearms or hanging—contributing to a higher fatality rate, while women are more likely to use less lethal methods and to access support services earlier in the course of their illness (World Health Organization, 2019; Centers for Disease Control and Prevention, 2022).

Although MDD commonly begins around the age of 40, recent trends show increasing prevalence among adolescents and young adults, partly driven by rising substance misuse, academic stress, and social media-related distress (Navneet Bains & Abdijadid, 2023). This demographic shift signals the need for earlier screening and targeted interventions that resonate with younger populations.

Social isolation remains another strong risk factor for MDD, particularly among individuals who are grieved, divorced, or living alone (National Academies of Sciences, Engineering, and Medicine, 2020). Such individuals often lack protective interpersonal bonds, which are crucial for emotional buffering during periods of psychological strain. Additionally, MDD often co-occurs with other psychiatric disorders—particularly anxiety disorders, panic disorder, obsessive-compulsive disorder, and social phobia (Goes et al., 2012). These comorbidities not only complicate diagnosis and treatment but also significantly elevate suicide risk, especially when left unmanaged.

Depression is also more prevalent in elderly individuals who are troubled with chronic physical illnesses such as diabetes, cardiovascular disease, or pulmonary disorders. Moreover, individuals residing in rural settings often face higher rates of untreated depression due to limited access to care, mental health stigma, and socioeconomic disadvantage (Williamson, 2000). These multidimensional patterns underscore the critical importance of context-aware, equitable mental health services that address structural, cultural, and biological vulnerabilities across populations.

2.2. Impact of MDD on Adults' Lives

Major Depressive Disorder (MDD) has profound and wide-ranging effects on adult functioning, extending far beyond emotional suffering. It interferes with occupational productivity, social roles, interpersonal relationships, and self-care.

Adults with MDD frequently experience significant cognitive impairments—such as reduced attention, decision-making difficulties, and slowed information processing—which affect job performance and daily responsibilities (Perinin et al., 2019). These deficits can perpetuate cycles of stress and withdrawal, often leading to unemployment, financial instability, or social disconnection.

Crucially, MDD is associated with increased all-cause mortality and a reduction in life expectancy by an estimated 7 to 11 years (Plana-Ripoll et al., 2019). While suicide contributes to this mortality risk, the majority of premature deaths result from comorbid medical conditions—such as cardiovascular disease, stroke, diabetes, and chronic respiratory disorders—that are exacerbated by depression. Biologically, this connection is mediated by inflammatory markers, hypothalamic-pituitary-adrenal (HPA) axis dysregulation, and lifestyle factors such as physical inactivity, poor nutrition, smoking, and reduced treatment adherence.

MDD rarely occurs in isolation. Comorbidities with anxiety disorders, substance use disorders, obsessive-compulsive disorder, and personality disorders are common and significantly worsen prognosis. These co-occurring conditions can heighten emotional dysregulation, complicate diagnosis, increase resistance to treatment, and elevate the risk of suicidal behavior (Berk et al., 2023).

Research indicates that depression prevalence is significantly higher among older adults managing chronic physical conditions, including diabetes, cardiovascular disease, and pulmonary disorders (National Institute on Aging [NIA], 2025). This relationship is particularly pronounced in rural populations, where Williamson's (2000) seminal work identified systemic barriers to treatment, including healthcare access limitations, persistent mental health stigma, and socioeconomic disparities. These findings collectively highlight the need for integrated care models that address both medical and mental health needs while accounting for geographic, cultural, and structural determinants of health equity.

3. Efficacy of Antidepressant Medicines

3.1. Overview of Antidepressant

Antidepressants play a central role in the pharmacological treatment of Major Depressive Disorder (MDD). They primarily target monoaminergic neurotransmission—modulating serotonin, norepinephrine, and dopamine pathways—to alleviate depressive symptoms. However, their clinical effectiveness, onset of action, side-effect burden, and suitability for long-term use vary across drug classes and patient profiles, necessitating a tailored approach to treatment selection.

- **Selective Serotonin Reuptake Inhibitors (SSRIs)** are widely prescribed due to their tolerability and favorable safety profile, particularly in overdose situations. Medications such as fluoxetine, sertraline, and escitalopram enhance serotonergic signaling by inhibiting the reuptake of serotonin (Vaswani et al., 2003). They are often first-line agents for mild-to-moderate depression, especially in patients with comorbid anxiety. However, drawbacks, including sexual dysfunction, emotional blunting, and gastrointestinal side effects, can impair adherence (Carvalho et al., 2016).
- **Serotonin-norepinephrine reuptake Inhibitors (SNRIs),** such as venlafaxine and duloxetine, also inhibit norepinephrine reuptake, offering enhanced efficacy in patients with chronic pain, somatic symptoms, or partial SSRI response (Celikyurt et al., 2012). Yet, they carry a higher risk of withdrawal symptoms and may elevate blood pressure, requiring careful monitoring.
- **Tricyclic Antidepressants (TCAs)** like amitriptyline and nortriptyline remain potent options for treatment-resistant or melancholic depression. Their mechanism involves broad receptor antagonism, which contributes to their side-effect profile—sedation, anticholinergic effects, and cardiotoxicity—making them unsuitable for first-line use without supervision (Kamp et al., 2024).
- **Monoamine Oxidase Inhibitors (MAOIs),** including phenelzine and tranylcypromine, increase synaptic monoamine levels by inhibiting enzymatic breakdown. They are effective for atypical and refractory depression but are limited by dietary restrictions and the risk of hypertensive crises (Giménez-Palomo et al., 2023).
- **Novel antidepressants** offer unique pharmacological profiles. Agomelatine, a melatonergic agonist and 5-HT2C antagonist, improves sleep regulation and anhedonia. Bupropion, a norepinephrine-dopamine reuptake inhibitor, is often preferred in cases of lethargy, hypersomnia, or SSRI-induced sexual dysfunction (Anttila & Leinonen, 2001; Stahl et al., 2004).
- **Rapid-acting agents** like ketamine and esketamine represent a shift in managing acute suicidality and treatment resistance. Acting on NMDA receptors, they induce rapid antidepressant effects via glutamatergic

modulation and neuroplasticity. While effective in the short term, concerns persist regarding long-term safety and accessibility (Seillier et al., 2022).

3.2. Recent Research Trends

The evolving landscape of antidepressant research reflects a transition from generalized pharmacotherapy to precision psychiatry. A landmark meta-analysis by Cipriani et al. (2018) synthesized data from over 21 antidepressants, demonstrating their overall efficacy compared to placebo while underscoring meaningful differences in tolerability and onset of action.

- **Pharmacogenetics** has emerged as a promising avenue to improve treatment outcomes. Genetic polymorphisms—particularly in cytochrome P450 enzymes (CYP2D6, CYP2C19) and the serotonin transporter gene (5-HTTLPR)—affect drug metabolism and therapeutic response. Integrating genotyping into clinical practice could reduce trial-and-error prescribing and enhance adherence (Fleisher, 2024; Gervasini et al., 2010).
- **Neuroimaging studie**s contribute to identifying biomarkers for MDD and treatment response. Abnormalities in the default mode network, prefrontal-limbic circuits, and amygdala hyperactivity are associated with depressive states and may predict treatment responsiveness (Zhang et al., 2024).
- **Innovative treatments,** including NMDA antagonists (e.g., Esketamine), anti-inflammatory agents, and psychedelic-assisted therapies, are being rigorously investigated. Real-world data highlight Eetamine's rapid reduction of suicidal ideation; however, its efficacy in long-term management remains questionable (Pan et al., 2024).
- **Adjunctive therapies**—such as transcranial magnetic stimulation (TMS), phototherapy, and acupuncture—have demonstrated moderate efficacy and are increasingly integrated into multimodal treatment strategies. Additionally, novel hypotheses, such as astrocytic dysfunction, offer fresh perspectives on treatment resistance and the neurobiology of mood disorders (Cui et al., 2024).

Overall, current research supports a shift toward **mechanism-based** prescribing and individualized care models, moving beyond symptom suppression to target the underlying neurobiological and psychosocial contributors to major depressive disorder (MDD).

4. Evidence-Based Intervention Protocols

4.1. Rational for Protocol Development

Developing an evidence-based intervention protocol is essential for structuring effective and replicable treatment plans for MDD. Major Depressive Disorder is a complex and multifaceted condition, and treatment must be informed by the latest clinical guidelines, empirical evidence, and individualized considerations. A structured protocol reduces variability in clinical decisions and mitigates reliance on trial-and-error approaches. It also facilitates personalized care by integrating validated tools and treatment algorithms that improve response rates and reduce unnecessary delays in achieving remission (Miklowitz et al., 2007).

4.2. Target Population

This protocol is designed for adults aged 18 to 65 diagnosed with Major Depressive Disorder (MDD) based on DSM-5 criteria. Inclusion should consider diverse clinical presentations, including those with comorbid anxiety, somatic symptoms, or prior treatment failures.

4.3. Treatment Protocol

4.3.1. Screening and Diagnosis

A comprehensive diagnostic workup begins with a clinical interview and standardized assessments such as the PHQ-9, HAM-D, or BDI-II (Kato et al., 2024). Screening for comorbid psychiatric disorders (e.g., anxiety, substance use, personality disorders) is crucial for treatment planning. Differential diagnosis must also consider medical conditions (e.g., hypothyroidism, vitamin B12 deficiency) and psychosocial influences. Integrating cultural, developmental, and contextual factors into case formulation supports individualized care.

4.3.2. Medication Selection

- **First-line Medications**, including SSRIs and SNRIs, due to their balanced efficacy and tolerability (Houglum et al., 2024). They are particularly effective in moderate depression and anxiety-related cases. First-line SSRI/SNRI use aligns with APA (2020) and NICE (2022) guidelines, supporting their foundational role in clinical practice.
- **Second line Medications:** If there is insufficient response after 4–6 weeks or intolerable side effects emerge, a switch to atypical antidepressants—such as bupropion or mirtazapine—may be warranted (Santarsieri & Schwartz, 2015). Mirtazapine is especially useful in individuals with insomnia or appetite loss due to its sedative and orexigenic properties (Anttila & Leinonen, 2001). Bupropion, with its dopaminergic and noradrenergic effects, may be preferable in cases marked by fatigue, hypersomnia, or SSRI-induced sexual dysfunction (Stahl et al., 2004; Patel et al., 2016).
- **Third-Line Medications:** For treatment-resistant cases, tricyclic antidepressants (TCAs)—such as amitriptyline—may be considered, although they necessitate careful cardiac and side-effect monitoring. Alternatively, agomelatine, which targets circadian regulation, may be effective in patients with pronounced anhedonia or disrupted sleep-wake cycles (Mamatha, 2017).
- **Individualized Treatment Planning:** Tailoring treatment to the individual's clinical profile, history, and preferences enhances therapeutic outcomes and promotes adherence (Su et al., 2024). *Key considerations include:*
    - Previous treatment response and side-effect profiles.
    - Co-existing medical or psychiatric conditions.
    - Patient preferences and expectations.

Where available, pharmacogenetic testing—particularly regarding cytochrome P450 enzyme variants (e.g., CYP2D6, CYP2C19)—can assist in optimizing medication selection and dosing, especially in cases of prior nonresponse or adverse drug reactions (Gervasini et al., 2010; Fleisher, 2024). This precision-medicine approach is increasingly recognized for its role in reducing trial-and-error prescribing.

4.3.3. Monitoring and Adjustments

Monitoring during the acute phase (initial 6–8 weeks) is essential. Biweekly evaluations should assess symptom progression, adverse effects, and suicide risk.

Adjustment strategies include:

- Dose optimization.
- Class switching.
- Augmentation (e.g., with atypical antipsychotics, lithium, clozapine, among others).
- Integration of psychotherapy.

Sustained absence of symptoms or remission should be followed by continuation therapy for 6–12 months. In recurrent cases, long-term maintenance may be necessary. Psychoeducation and shared decision-making improve adherence and therapeutic alliance.

4.3.4. Integrative/Holistic Approaches (Pharmacotherapy and Psychotherapy)

The protocol encourages the combination of pharmacotherapy and psychotherapy to enhance the treatment outcome in MDD. The evidence in the literature supports the argument that using both approaches leads to improved results compared to using only one. Some of the integrated approaches are as follows:

- **Cognitive Behavioral Therapy (CBT)**: CBT assesses, contests, and alters maladaptive ideas that perpetuate depression. Behavioral techniques, such as cognitive restructuring, activity scheduling, behavioral activation/experimentation, and mindful meditation, are employed to enhance enjoyable activities for the treatment of anhedonia (Crawley, 2023). CBT can be delivered in either individual or group modes. It is brief (e.g., 20 sessions) and issue-oriented.
- **Acceptance and Commitment Therapy (ACT):** ACT is a scientifically supported approach rooted in behavioral science and mindfulness. Its primary focus is on encouraging psychological flexibility by helping individuals acknowledge their thoughts and emotions without judgment while taking purposeful actions aligned with their core values. ACT uses methods such as acceptance strategies, cognitive defusion, mindfulness practices, and values-of-self-driven action planning. ACT is especially beneficial in chronic or treatment-resistant cases and has been shown to enhance engagement in meaningful life activities (Bai et al., 2020).

- **Interpersonal Therapy (IPT):** IPT is a systematic and concise technique targeting social factors that perpetuate depression. It can be delivered in individual or group formats. It is transient and issue-oriented. IPT has demonstrated efficacy across various age groups and cultural settings (Dietz et al., 2018).
- **Problem-solving therapy (PST)** instructs individuals to articulate personal issues, generate multiple solutions, select the most effective one, execute it, and evaluate its efficacy (Nezu et al., 2005). A moderate body of data indicates its efficacy in treating depression

5. Conclusion

Major Depressive Disorder (MDD) research has made remarkable progress toward precision medicine, leveraging genetic testing (e.g., CYP450 polymorphisms) and neuroimaging biomarkers (e.g., amygdala & hyperactivity) to guide personalized treatment (Fleisher, 2024; Zhang et al., 2024). These advances align with the RDoC framework, emphasizing biologically informed interventions (Le-Niculescu et al., 2021). However, clinical translation remains hindered by systemic barriers, including limited insurance coverage for biomarker testing and unequal access to specialized care. Additionally, methodological limitations—such as the exclusion of complex patients in trials, high placebo responses, and a lack of long-term efficacy data reduce the real-world applicability of findings.

Moving forward, MDD research must prioritize three key areas:

- *Mechanistic Clarity* – Longitudinal studies on glutamatergic modulation and neuroplasticity to refine novel treatments.
- *Implementation Science* – Scaling cost-effective interventions (e.g., digital CBT) to bridge the global treatment gap.
- *Ethical Innovation* – Harnessing AI for predictive analytics while safeguarding patient privacy.

Beyond science, structural reforms are essential—investing in clinician training, equitable access to therapies, and policies that address socioeconomic disparities. The future of MDD management hinges on integration: combining cutting-edge biological insights with psychosocial support in patient-centered models.

Ultimately, while precision psychiatry holds transformative potential, *its success depends on translating breakthroughs into accessible and equitable care.* Only by addressing both the biological and systemic dimensions can we mitigate the global burden of MDD.

Compliance with ethical standards

Acknowledgments

This review was written with the support of AI-powered tools to assist in drafting and organizing ideas. However, careful effort was made to revise, paraphrase, and refine the content to ensure that it reflects original thought, human authorship, and academic integrity.

Disclosure of conflict of interest

None declared. The author affirms that there are no financial, personal, political, or religious interests that could have influenced the work reported in this manuscript.

Financial Support

This work did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

References

[1] Anttila, Sami AK, & Leinonen, Esa VJ. (2001). A review of the pharmacological and clinical profile of mirtazapine. CNS drug reviews, 7(3), 249-264.

[2] Berk, Michael, Köhler-Forsberg, Ole, Turner, Megan, Penninx, Brenda WJH, Wrobel, Anna, Firth, Joseph, . . . Momen, Natalie C. (2023). Comorbidity between major depressive disorder and physical diseases: a comprehensive review of epidemiology, mechanisms and management. World Psychiatry, 22(3), 366-387.

[3] Bai, Z., Luo, S., Zhang, L., Wu, S., & Chi, I. (2020). Acceptance and Commitment Therapy (ACT) to reduce depression: A systematic review and meta-analysis. Journal of affective disorders, 260, 728–737. https://doi.org/10.1016/j.jad.2019.09.040

[4] Berk, M., Köhler-Forsberg, O., Turner, M., Penninx, B.W.J.H., Wrobel, A., Firth, J., Loughman, A., Reavley, N.J., McGrath, J.J., Momen, N.C., Plana-Ripoll, O., O'Neil, A., Siskind, D., Williams, L.J., Carvalho, A.F., Schmaal, L., Walker, A.J., Dean, O., Walder, K., Berk, L., Dodd, S., Yung, A.R. and Marx, W. (2023), Comorbidity between major depressive disorder and physical diseases: a comprehensive review of epidemiology, mechanisms and management. World Psychiatry, 22: 366-387. https://doi.org/10.1002/wps.21110

[5] Carvalho, André F, Sharma, Manu S, Brunoni, André R, Vieta, Eduard, & Fava, Giovanni A. (2016). The safety, tolerability and risks associated with the use of newer generation antidepressant drugs: a critical review of the literature. Psychotherapy and psychosomatics, 85(5), 270-288.

[6] Celikyurt, Ipek Komsuoglu, Mutlu, Oguz, & Ulak, Guner. (2012). Serotonin noradrenaline reuptake inhibitors (SNRIs). In Effects of Antidepressants. IntechOpen.

[7] Centers for Disease Control and Prevention. (2022). Suicide data and statistics. Retrieved from https://www.cdc.gov/suicide/facts/data.html

[8] Cipriani, Andrea, Furukawa, Toshi A, Salanti, Georgia, Chaimani, Anna, Atkinson, Lauren Z, Ogawa, Yusuke, . . . Higgins, Julian PT. (2018). Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. The Lancet, 391(10128), 1357-1366.

[9] Crawley, Daisy Victoria. (2023). Using computation to understand change in psychological therapy: a reinforcement learning framework of behavioural activation for depression.

[10] Cui, Lulu, Li, Shu, Wang, Siman, Wu, Xiafang, Liu, Yingyu, Yu, Weiyang, . . . Li, Baoman. (2024). Major depressive disorder: hypothesis, mechanism, prevention and treatment. Signal Transduction and Targeted Therapy, 9(1), 30.

[11] Dietz, Laura J, Weinberg, Rebecca, & Mufson, Laura. (2018). Family-based interpersonal psychotherapy for depressed preadolescents: Clinician guide. Oxford University Press.

[12] Enck, Paul, & Zipfel, Stephan. (2019). Placebo effects in psychotherapy: a framework. Frontiers in psychiatry, 10, 456.

[13] Elias, E., Zhang, A. Y., & Manners, M. T. (2022). Novel pharmacological approaches to the treatment of depression. Life, 12(2), 196. https://doi.org/10.3390/life12020196

[14] Fleisher, Rebecca. (2024). Assessing Utilization and Outcomes of Pharmacogenomic Testing Among Children and Adolescents in Outpatient Psychiatric Treatment: A Quality Improvement Project.

[15] Gervasini, Guillermo, Benítez, Julio, & Carrillo, Juan Antonio. (2010). Pharmacogenetic testing and therapeutic drug monitoring are complementary tools for optimal individualization of drug therapy. European journal of clinical pharmacology, 66, 755-774.

[16] Giménez-Palomo, Anna, Chamdal, Anjli K, Gottlieb, Natalie, Lotfaliany, Mojtaba, & Stokes, RA. Efficacy and tolerability of MAOIs for the treatment of depressive episodes in mood disorders: a systematic review and network meta-analysis.

[17] Goes, FS, McCusker, MG, Bienvenu, OJ, Mackinnon, DF, Mondimore, FM, Schweizer, B, . . . Consortium, National Institute of Mental Health Genetics Initiative Bipolar Disorder. (2012). Co-morbid anxiety disorders in bipolar disorder and major depression: familial aggregation and clinical characteristics of co-morbid panic disorder, social phobia, specific phobia and obsessive-compulsive disorder. Psychological medicine, 42(7), 1449-1459.

[18] Houglum, Joel E, Harrelson, Gary L, & Seefeldt, Teresa M. (2024). Drugs for Treating Psychiatric Disorders. In Principles of Pharmacology for Athletic Trainers (pp. 236-267). Routledge.

[19] Kamp, Caroline Barkholt, Petersen, Johanne Juul, Faltermeier, Pascal, Juul, Sophie, Siddiqui, Faiza, Barbateskovic, Marija, . . . Hengartner, Michael Pascal. (2024). Beneficial and harmful effects of tricyclic antidepressants for adults with major depressive disorder: a systematic review with meta-analysis and trial sequential analysis. BMJ Ment Health, 27(1).

[20] Karrouri, Rabie, Hammani, Zakaria, Benjelloun, Roukaya, & Otheman, Yassine. (2021). Major depressive disorder: Validated treatments and future challenges. World journal of clinical cases, 9(31), 9350.

[21] Kato, Masaki, Kikuchi, Toshiaki, Watanabe, Koichiro, Sumiyoshi, Tomiki, Moriguchi, Yoshiya, Oudin Åström, Daniel, & Christensen, Michael Cronquist. (2024). Goal attainment scaling for depression: validation of the JAPANESE GAS-D tool in patients with major depressive disorder. Neuropsychiatric Disease and Treatment, 49-60.

[22] Lambert, Michael J. (2005). Early response in psychotherapy: Further evidence for the importance of common factors rather than "placebo effects". Journal of clinical psychology, 61(7), 855-869.

[23] Le-Niculescu, H, Roseberry, K, Gill, SS, Levey, DF, Phalen, PL, Mullen, J, . . . Davis, H. (2021). Precision medicine for mood disorders: objective assessment, risk prediction, pharmacogenomics, and repurposed drugs. Molecular Psychiatry, 26(7), 2776-2804.

[24] Liwinski, Timur, & Lang, Undine E. (2023). Folate and its significance in depressive disorders and suicidality: a comprehensive narrative review. Nutrients, 15(17), 3859.

[25] Malhi, Gin S, & Mann, J John. (2018). Course and prognosis. Lancet, 392(10161), 2299-2312.

[26] Mamatha, V. (2017). A Study of Efficacy and Safety Profile of Amitriptyline and Agomelatine in Major Depressive Disorder Rajiv Gandhi University of Health Sciences (India)].

[27] Martz, Ryan, Uribe, Alejandra, Jimenez-Price, Gladys, Cupeles, Agnelis Hernández, Ramirez, Juan G Maldonado, & Madera, Christian. (n.d.). Novel and Established Treatment Modalities for Treatment-Resistant Depression: a Meta-Analysis.

[28] Miklowitz, David J, Otto, Michael W, Frank, Ellen, Reilly-Harrington, Noreen A, Wisniewski, Stephen R, Kogan, Jane N, . . . Gyulai, Laszlo. (2007). Psychosocial treatments for bipolar depression: a 1-year randomized trial from the Systematic Treatment Enhancement Program. Archives of general psychiatry, 64(4), 419-426.

[29] Millard, Elizabeth. (2022). Depression: DSM Diagnostic Criteria and Treatment Overview. https://www.medcentral.com/behavioral-mental/depression/assessment-diagnosis-adherence-depression

[30] Möller, Hans-Jürgen. (2008). Outcomes in major depressive disorder: the evolving concept of remission and its implications for treatment. The World Journal of Biological Psychiatry, 9(2), 102-114.

[31] Navneet Bains, & Abdijadid, Sara. (2023). Major Depressive Disorder. StatPearls Publishing LLC.

[32] Nezu, Christine Maguth, D'Zurilla, THOMAS J, & Nezu, Arthur M. (2005). Problem-solving therapy: Theory, practice, and application to sex offenders. Social problem solving and offenders: Evidence, evaluation and evolution, 103-123.

[33] National Academies of Sciences, Engineering, and Medicine. (2020). Social isolation and loneliness in older adults: Opportunities for the health care system (Chapter 4). National Academies Press. https://www.ncbi.nlm.nih.gov/books/NBK557971/

[34] National Institute on Aging. (2025, February 5). Depression and older adults. U.S. Department of Health and Human Services, National Institutes of Health. https://www.nia.nih.gov/health/depression-and-older-adults

[35] Pan, Zihang, Park, Caroline, Brietzke, Elisa, Zuckerman, Hannah, Rong, Carola, Mansur, Rodrigo B, . . . McIntyre, Roger S. (2019). Cognitive impairment in major depressive disorder. CNS spectrums, 24(1), 22-29.

[36] Pan, Y., Gorenflo, M.P., Davis, P.B. et al. Suicidal ideation following ketamine prescription in patients with recurrent major depressive disorder: a nation-wide cohort study. Transl Psychiatry 14, 327 (2024). https://doi.org/10.1038/s41398-024-03033-4

[37] Perini, G., Cotta Ramusino, M., Sinforiani, E., Bernini, S., Petrachi, R., & Costa, A. (2019). Cognitive impairment in depression: recent advances and novel treatments. Neuropsychiatric disease and treatment, 15, 1249–1258. https://doi.org/10.2147/NDT.S199746

[38] Patel, K., Allen, S., Haque, M. N., Angelescu, I., Baumeister, D., & Tracy, D. K. (2016). Bupropion: a systematic review and meta-analysis of effectiveness as an antidepressant. Therapeutic advances in psychopharmacology, 6(2), 99–144. https://doi.org/10.1177/2045125316629071

[39] Richelson, Elliott. (2001). Pharmacology of antidepressants. Mayo Clinic Proceedings,

[40] Santarsieri, Daniel, & Schwartz, Thomas L. (2015). Antidepressant efficacy and side-effect burden: a quick guide for clinicians. Drugs in context, 4.

[41] Seillier, Célia, Lesept, Flavie, Toutirais, Olivier, Potzeha, Fanny, Blanc, Manuel, & Vivien, Denis. (2022). Targeting NMDA receptors at the neurovascular unit: Past and future treatments for central nervous system diseases. International journal of molecular sciences, 23(18), 10336.

[42] Stahl, Stephen M, Pradko, James F, Haight, Barbara R, Modell, Jack G, Rockett, Carol B, & Learned-Coughlin, Susan. (2004). A review of the neuropharmacology of bupropion, a dual norepinephrine and dopamine reuptake inhibitor. Primary care companion to the Journal of clinical psychiatry, 6(4), 159.

[43] Tolentino, Julio C, & Schmidt, Sergio L. (2018). DSM-5 criteria and depression severity: implications for clinical practice. Frontiers in psychiatry, 9, 450.

[44] Vaswani, Meera, Linda, Farzana Kadar, & Ramesh, Subramanyam. (2003). Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review. Progress in neuro-psychopharmacology and biological psychiatry, 27(1), 85-102.

[45] Zhang, Yajuan, Huang, Chu-Chung, Zhao, Jiajia, Liu, Yuchen, Xia, Mingrui, Wang, Xiaoqin, . . . Zheng, Yanting. (2024). Dysfunction in sensorimotor and default mode networks in major depressive disorder with insights from global brain connectivity. Nature Mental Health, 1-11.

[46] World Health Organization. (2019). Suicide in the world: Global health estimates. Retrieved from https://apps.who.int/iris/bitstream/handle/10665/326948/WHO-MSD-MER-19.3-eng.pdf

[47] Williamson, G. M., Shaffer, D. R., & Parmelee, P. A. (Eds.). (2000). Physical illness and depression in older adults: A handbook of theory, research, and practice (1st ed.). Springer. https://doi.org/10.1007/b107734

[48] Su, J., Yang, L., Sun, Z., & Zhan, X. (2024). Personalized drug therapy: Innovative concept guided with proteoformics. Molecular & Cellular Proteomics: MCP, 23(3), 100737. https://doi.org/10.1016/j.mcpro.2024.100737